Major events:

Sh Pharma (02607): The production of Apomist tablets at Changzhou Pharmaceutical Factory has been approved.

Luye Pharma (02186): Zanidatam injection (Lubiprostone for injection) has been approved for listing in mainland China.

Shandong Xinhua (00719): Azithromycin dry suspension has passed the consistency evaluation of quality and efficacy for generic drugs.

Hutchmed (china) (00013) and Innovent Bio (01801) jointly announced that Elunate (sulibactam sodium) has been conditionally approved by the China National Medical Products Administration for the treatment of advanced endometrial carcinoma.

Zijin Mining Group (02899): The La Arena gold mine in Peru and Phase II project have completed the delivery.

Arcturus (06086) included in the Hang Seng Hong Kong-listed Biotech Index components.

First Pacific (00142) plans to spin off its stake in Maynilad for independent listing on the Philippine Stock Exchange.

Guangzhou Automobile Group (02238) and its wholly-owned subsidiary Guangzhou Capital plan to transfer 18.82% of their equity in Juwan Technology Research to the industrial conglomerates of Guangzhou Automobile Group.

Business performance:

Yuexiu Property (00123) recorded a cumulative contract sales of approximately 101.02 billion yuan in the first 11 months, a year-on-year decrease of around 24%.

Agile Group (03383) recorded a total presale amount of 14.75 billion yuan in the first 11 months, a year-on-year decrease of 64.81%.

Zhenro PPT (06158) recorded a cumulative contracted sales amount of around 5.99 billion yuan in the first 11 months, a year-on-year decrease of 58.6%.

For more details, please refer to the CITIC Securities website ().